CN111202753A - Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method - Google Patents

Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method Download PDF

Info

Publication number
CN111202753A
CN111202753A CN202010101963.6A CN202010101963A CN111202753A CN 111202753 A CN111202753 A CN 111202753A CN 202010101963 A CN202010101963 A CN 202010101963A CN 111202753 A CN111202753 A CN 111202753A
Authority
CN
China
Prior art keywords
parts
piglet
stearate
preventing
swine fever
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010101963.6A
Other languages
Chinese (zh)
Inventor
刘自逵
胡兴平
伍勇
邹才云
柳高峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING VICA BIOTECHNOLOGY CO LTD
Hunan Canzoho Biological Technology Co ltd
Original Assignee
BEIJING VICA BIOTECHNOLOGY CO LTD
Hunan Canzoho Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING VICA BIOTECHNOLOGY CO LTD, Hunan Canzoho Biological Technology Co ltd filed Critical BEIJING VICA BIOTECHNOLOGY CO LTD
Priority to CN202010101963.6A priority Critical patent/CN111202753A/en
Publication of CN111202753A publication Critical patent/CN111202753A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Abstract

The invention relates to an antibody drug combination for preventing and treating piglet infection and improving piglet immunity and a swine fever antibody application method, which comprises the following components in parts by weight: 5-20 parts of ceftiofur hydrochloride, 0.01-0.05 part of beneficial bacteria, 1-10 parts of stearate and 50-80 parts of vegetable oil, comprehensively prevents and treats wound infection of piglets, improves the immunity of organisms, and enhances the antiviral and anti-inflammatory capabilities.

Description

Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method
Technical Field
The invention relates to the field of veterinary drugs, in particular to a drug combination for preventing and treating piglet infection, improving immunity and improving swine fever antibody and a using method thereof.
Background
At present, the phenomena of high morbidity and mortality of piglets in a delivery house and postpartum inflammation of sows commonly exist in a pig farm, the delivery house is the core of the whole pig farm, and the economic benefit of the whole pig farm is influenced on a fixed scale by the number of weaned piglets and the health level of the sows. Therefore, the method is especially important for searching the medicine which can effectively prevent and treat diseases, improve the survival rate of piglets, and has long medicine effect time, high safety and low medicine cost. The health care of piglets by the Ennosaxacin medicines for farmers is available in the market, but the Ennosacin medicines have obvious inhibition effect on the bone growth and development of young animals; while chloramphenicol drugs and sulfonamides have serious inhibition effect on the development of immune function of piglets, and long-acting oxytetracycline is easy to cause bacterial drug resistance. Based on the above, the ceftiofur serving as the animal third-generation cephalosporin antibiotics has the characteristics of wide antibacterial spectrum, strong antibacterial activity, certain antibacterial activity on gram-positive bacteria, gram-negative bacteria and spirochetes, long effective action time and difficult generation of drug resistance. Although a plurality of ceftiofur products such as ceftiofur hydrochloride injection, ceftiofur sodium, long-acting ceftiofur hydrochloride suspension, compound ceftiofur hydrochloride suspension and the like are continuously developed in recent years, the blank of the medicine is filled to a certain extent. However, a plurality of short-acting ceftiofur products exist in the market at present, the effective time is less than three days, and the blank period of organism protection is easily caused, so that piglets are infected with diseases in the blank period, and in addition, a few famous 10% short-acting ceftiofur injection produced in China have high cost, 2-3 yuan/mL, so that many ordinary farmers are prohibited.
The invention can not only realize long-acting antibiosis and immunity regulation, but also play the characteristics of quick drug effect and slow release in animals, reduce the morbidity and mortality of piglets in delivery rooms of pig farms and improve the economic benefit of the pig farms.
Disclosure of Invention
The invention aims to provide an antibody drug combination for preventing and treating piglet infection and improving immunity and a swine fever antibody application method.
The purpose of the invention is realized by the following ways:
a formula of an antibody drug combination for preventing and treating piglet infection and improving immunity and swine fever is characterized in that: comprises the following components: ceftiofur hydrochloride, beneficial bacteria, stearate and vegetable oil.
The weight ratio of the components is as follows: 5-20 parts of ceftiofur hydrochloride, 0.01-0.05 part of beneficial bacteria, 1-10 parts of stearate and 50-80 parts of vegetable oil.
Preferably, the weight ratio of the components can be as follows:
formula 1: 5-15 parts of ceftiofur hydrochloride, 0.01-0.03 part of beneficial bacteria, 1-8 parts of stearate and 50-70 parts of vegetable oil.
And (2) formula: 5-10 parts of ceftiofur hydrochloride, 0.01-0.02 part of beneficial bacteria, 1-5 parts of stearate and 50-60 parts of vegetable oil.
The invention also provides a use method of the antibody drug combination for preventing and treating piglet infection and improving immunity and swine fever, which comprises the following steps:
the method comprises the following steps: when the piglets are cut teeth, broken tails and castrated, the piglets are injected into the head and neck part of the piglets by intramuscular injection once, 1 ml each time.
The method 2 comprises the following steps: the weaned pig is injected into the head and neck of the weaned pig by intramuscular injection once, 1 ml each time.
The method 3 comprises the following steps: the piglets inoculated with the swine fever vaccine are injected intramuscularly once per head and neck at the same time, 1 ml each time.
Through the effect tests of the invention for preventing and treating the infection of piglets and improving the immunity of piglets and the swine fever antibody, the invention can be observed to prevent and treat the infection of piglets, prolong the drug effect, and improve the immunity of piglets and the swine fever antibody level.
Detailed Description
The present invention will be described in further detail below with reference to specific examples.
Example 1: beneficial bacterium formula
Formula 1: 0.01g of bacillus subtilis and 0.02g of mycobacterium subtilis.
And (2) formula: 0.01g of bacillus subtilis and 0.01g of mycobacterium subtilis.
And (3) formula: 0.02g of bacillus subtilis and 0.01g of mycobacterium subtilis.
Example 2: stearate formula
Formula 1: 0.5g of aluminum stearate and 0.5g of sodium stearate.
And (2) formula: 1g of aluminum stearate and 1g of sodium stearate.
And (3) formula: 2g of aluminum stearate and 1g of sodium stearate.
Example 3: vegetable oil formulation
Formula 1: 45g of soybean oil and 5g of sesame oil.
And (2) formula: 40g of soybean oil and 10g of sesame oil.
And (3) formula: 35g of soybean oil and 15g of sesame oil.
Example 4: pharmaceutical combination formula
Formula 1: 5g of ceftiofur hydrochloride, 0.01g of beneficial bacteria, 1g of stearate and 50g of vegetable oil, and the ceftiofur hydrochloride, the beneficial bacteria, the stearate and the vegetable oil are mixed to prepare the injection.
And (2) formula: 7g of ceftiofur hydrochloride, 0.02g of beneficial bacteria, 1.5g of stearate and 55g of vegetable oil, and the ceftiofur hydrochloride, the beneficial bacteria, the stearate and the vegetable oil are mixed to prepare the injection.
And (3) formula: 10g of ceftiofur hydrochloride, 0.02g of beneficial bacteria, 2g of stearate and 60g of vegetable oil, and the ceftiofur hydrochloride, the beneficial bacteria, the stearate and the vegetable oil are mixed to prepare the injection.
And (4) formula: 12g of ceftiofur hydrochloride, 0.03g of beneficial bacteria, 2.5g of stearate and 65g of vegetable oil, and the ceftiofur hydrochloride, the beneficial bacteria, the stearate and the vegetable oil are mixed to prepare the injection.
And (5) formula: the injection comprises 15g of ceftiofur hydrochloride, 0.03g of beneficial bacteria, 3g of stearate and 70g of vegetable oil, and the ceftiofur hydrochloride, the beneficial bacteria, the stearate and the vegetable oil are mixed to prepare the injection.
Example 5: the present invention test for preventing infection of piglets
The effect of the invention on preventing piglet infection is evaluated by detecting differences between piglets using and not using the invention when the piglets cut teeth, cut tails and castrate. The test is carried out in Xinkang livestock breeding Limited company of Liuyang city, Hunan province, healthy 5-day-old piglets are selected for 4 litters with 12 piglets per litter and are randomly divided into a group of the invention and a blank control group with 24 piglets per group. When the piglet is subjected to tooth cutting, tail breaking and castration, the piglet disinfection treatment device is injected into the head and neck part of the piglet once in an intramuscular mode, 1 ml of the disinfection treatment device is used for every head of a blank control group, and conventional external disinfection treatment is carried out on every head of the blank control group. The observation was continued for one week. The piglets in the invention are not infected, and 3 piglets in the blank group are infected, and the infection rate is 12.5%. The invention can prevent the infection of the piglets after tooth cutting, tail breaking and castration.
Example 6: long term test of the present invention
The long-acting effect of ceftiofur hydrochloride is evaluated by measuring the pharmacokinetics of the ceftiofur hydrochloride through intramuscular injection of the ceftiofur hydrochloride to piglets.
1. Method 1.1 test animals in Xinkang animal husbandry Limited company, Hunan, randomly select 6 healthy hybrid big and white pigs, age about 70 days, weight 22-25kg, freely drink water, feed the feed without drugs, regularly feed the feed twice every day, feed the feed for one week before the administration, and adapt to the environment. In the test, one-time injection is carried out on each back leg muscle, and the administration dosage is 5mg/kg body weight of ceftiofur hydrochloride.
1.2 sample Collection and processing
After intramuscular injection of ceftiofur hydrochloride suspension injection into the neck of each group, 3ml of blood is collected in the anterior vena cava before 1, 4, 8, 11, 24, 48, 72, 96, 120 and 144h, the collected blood is placed in a heparin sodium anticoagulation tube, kept stand for 2h at room temperature, centrifuged at 2500rpm, and supernatant plasma is taken and stored at-20 ℃.
1.3 chromatographic conditions
A chromatographic column: agilent TC-C18 (5 μm, 4.6mmx150 mm); ultraviolet detector, detection wavelength: 266 nm; column temperature: 30 ℃, flow rate: 1.0 ml/min; sample size; 50 μ L, mobile phase 0.01mol/L ammonium acetate solution (A): methanol (B) (following a gradient elution procedure);
TABLE 1 gradient elution procedure
Time (minutes) Mobile phase A (%) Mobile phase B (%)
0~4 85 15
4~13 85→75 15→26
13~20 75→85 26→15
20~22 85 15
2. Results and analysis
The results of the blood concentration and time of the experimental animals are shown in Table 2.
TABLE 2 plasma concentration (μ g/ml) after intramuscular injection of ceftiofur
Time of day Number 1 Number 2 No. 3 Number 4 Number 5 Number 6 Mean ± deviation
1h 3.13 10.88 2.36 6.60 2.72 2.48 4.70±3.42
5h 7.72 10.35 4.28 9.55 6.22 7.91 7.67±2.21
8h 3.39 7.97 4.62 8.56 8.5 8.13 6.86±2.26
11h 5.66 6.24 4.61 7.96 6.66 5.59 6.12±1.14
24h (1 day) 2.07 2.04 2.26 3.05 2.73 3.73 2.65±0.66
48h (2 days) 0.85 0.76 0.32 1.21 1.23 1.25 0.94±0.37
72h（3 days) 0.46 0.36 0.62 0.74 0.51 0.79 0.58±0.17
96h (4 days) 0.29 0.30 0.22 0.45 0.25 0.26 0.30±0.08
120h (5 days) 0.22 0.26 0.24 0.32 0.23 0.20 0.24±0.09
144h (6 days) 0.12 0.13 0.16 0.21 0.17 0.13 0.18±0.03
As can be seen from Table 2, after intramuscular injection of the present invention, 6 pigs maintained effective blood levels (≧ 0.2 μ g/ml, minimum effective concentration of 0.2 μ g/ml) for 5 days, and No. 4 pig maintained effective blood levels for 6 days.
Discussion of 3
The invention can maintain the effective concentration for 5 days through the pharmacokinetics test of the piglet, which shows that the invention has long-acting effect.
Example 7: test of influence of the invention on several immune indexes of weaned piglets
Weaned piglets are randomly divided into a blank control group and the group of the invention according to the weight, blood samples of each group of piglets are taken at 7 days, 21 days and 35 days after injection, the concentrations of immunoglobulin IgA, immunoglobulin IgM, interferon (IFN-gamma), interleukin-4 (IL-4), interleukin-10 (IL-10), tumor necrosis factor α (INF- α) and the like in serum are detected, and the influence of the invention on immune indexes is evaluated.
1. Method 1.1 grouping and administration of test animals
Weaned piglets which are 23 days old and come from the same sow are evenly divided into 2 groups according to weight and sex, namely a blank control group and the invention group, wherein the invention group is injected neck intramuscularly according to the weight dose of 5mg/kg of ceftiofur hydrochloride, and the blank control group is injected with physiological saline with the same volume. The feeding conditions and immunization program were the same for each group during the experiment.
1.2 sample Collection and processing
Collecting blood from each group of anterior vena cava 5mL on 7 days, 21 days and 35 days after administration, standing in common glass blood collection tube for 2h, centrifuging at 2500rpm for 15min, collecting upper layer serum, packaging, and storing at-20 deg.C.
1.3 detection index
And the indexes of the immunoglobulin IgA, the immunoglobulin IgM, the interferon (IFN-gamma), the interleukin-4 (IL-4), the interleukin-10 (IL-10), the tumor necrosis factor α (INF- α) and the like are operated according to the requirements of the detection kit, and SPSS statistical software is adopted to compare results between the two groups.
2. Results and analysis
The detection results of the invention on the influence of immune indexes such as weaned pig immunoglobulin IgA, immunoglobulin IgM, interferon (IFN-gamma), interleukin-4 (IL-4), interleukin-10 (IL-10), tumor necrosis factor α (INF- α) and the like are shown in Table 3.
TABLE 3 results of the Effect of the invention on several immunological indices of weaned piglets
Figure 836834DEST_PATH_IMAGE002
Note: indicates significant difference (P < 0.05) from blank group-indicates no detection.
Immunoglobulin IgA: IgA concentrations increased in the group of the present invention on day 7 after administration compared to the blank control group; on day 21 post-dose, IgA concentrations remained higher in the groups of the invention than in the placebo group; on day 35 post-dosing, there was no difference between the groups of the invention and the blank control group.
Immunoglobulin IgM: on day 7 after administration, no immunoglobulin IgM was detected in the blank control group, but in the present group; on day 21 after administration, immunoglobulin IgM was still detectable in the groups of the present invention; on day 35 after dosing, no immunoglobulin IgM was detected between the groups of the invention and the placebo group.
Interferon (IFN- γ): the interferon (IFN-. gamma.) concentration of the group of the present invention was increased on the 7 th day after the administration, compared with the blank control group; on day 21 post-dose, the concentration of the group of the invention was still higher than that of the blank control group; on day 35 post-dosing, there was no difference between the groups of the invention and the blank control group.
Interleukin-4 (IL-4): compared with the blank control group, the interleukin-4 concentration of the group of the invention is increased on the 7 th day after the administration; on day 21 after administration, the IL-4 concentration in the present group was still higher than that in the blank control group; on day 35 post-dosing, there was no difference between the groups of the invention and the blank control group.
Interleukin-10 (IL-10): on day 7 after dosing, no IL-10 was detected in the blank control group, but in the present invention group; on day 21 after administration, IL-10 was still detectable in the groups of the invention; on day 35 post-dose, no IL-10 was detected between the groups of the invention and the placebo group.
Tumor necrosis factor α (INF- α) on day 7 after administration, no TNF α was detected in the placebo group but in the present invention, TNF α was still detected in the present invention on day 21 after administration, and TNF α was not detected in both the present invention and placebo groups on day 35 after administration.
Discussion of 3
Immunoglobulin IgA is used as an important immunoglobulin of weaned pigs, has an important effect on intestinal health of the weaned pigs, can improve the immunoglobulin IgA level in the weaned pigs within 21 days after administration, is beneficial to improving the defense capacity of organisms and relieving weaned stress and reloading stress of the weaned pigs, immunoglobulin IgM can not pass through blood vessel walls and mainly exists in blood, the sterilization, bacteriolysis, activation of complement and phagocyte are obviously improved, the IgM level in the weaned pigs can be improved within 7 days after administration, interferon (IFN-gamma) is maintained for 21 days after administration, interferon (IFN-gamma) has the effects of resisting virus, regulating immunity and the like, the interferon (IFN-gamma) can improve the gamma interferon level in the weaned pigs within 7 days after administration, the action time of the interferon-4 (IL-4) is maintained for 21 days after administration, cytokine produced by activated T lymphocytes stimulates B cells to synthesize the immunoglobulin, enhances the killing activity, the interleukin-4 (IL-4) is maintained for 21 days after administration, the interleukin-4 (IL-21 days after administration, the interleukin-4) is maintained for 7 days after administration, the interleukin-21 days after administration, the interleukin-84, the interleukin-21-10, the interleukin-21-10-7-10-5-10-5-10-one-day after administration, the administration of the immune response of the.
In conclusion, the invention can improve the defense capacity of weaned pigs and enhance the antiviral and anti-inflammatory capacities.
Example 8: test of influence of the invention on hog cholera virus antibody of weaned piglet
The method comprises the steps of randomly dividing 23-day-old weaned piglets into a blank control group and an invention group according to body weight, injecting physiological saline into the pigs at the age of 30 days in the same day as the blank control group, injecting the pigs at the age of 30 days in the same day as the invention group, injecting the swine fever vaccine into each group, detecting the level of the swine fever antibody in the weaned piglets from the age of 30 days to the end of a 58-day-old test, and evaluating the influence of two kinds of quick-acting treatment on the generation of specific antibody of the swine fever vaccine.
1. Method 1.1 grouping and administration of test animals
Weaned piglets which are 23 days old and come from the same sow are evenly divided into 2 groups according to weight and sex, namely a blank control group and the invention group, on the same day, the invention group is injected in neck muscle according to the body weight dose of 5mg/kg of ceftiofur hydrochloride, and the blank control group is injected with physiological saline with the same volume. The feeding conditions and immunization program were the same for each group during the experiment.
1.2 sample Collection and processing
Injecting hog cholera vaccine into each group at 30 days of age, collecting blood 5mL of anterior vena cava of each group at 44 days of age and 58 days of age, namely 7 days, 21 days and 35 days after injection speed doubling, standing in a common glass blood collection tube for 2h, centrifuging at 2500rpm for 15min, collecting upper layer serum, packaging, and storing at-20 deg.C to be tested.
1.3 detection index
The detection of classical swine fever virus antibodies is carried out according to the requirements of an American Edwardsiella (IDEXX) detection kit.
2. Results and analysis
The results of the detection of the influence of the antibody of the invention on the swine fever of weaned piglets are summarized in table 4.
TABLE 4 Effect of the invention on classical swine fever virus antibodies on weaned piglets results (expressed as blocking rate)
Figure 753975DEST_PATH_IMAGE004
Note: "-" indicates that no detection was made
According to the instructions of the U.S. Edesl IDEXX swine fever antibody detection kit. The more classical swine fever virus antibodies in the serum to be detected, the higher the blocking rate. Generally, the blocking rate and the coefficient of variation are evaluated.
1. The positive rate is as follows: the Blocking rate (Blocking) of the swine fever antibody is more than or equal to 40 percent, and the result is judged to be positive; if the ratio is more than 30% and less than Blocking and less than 40%, judging the result to be a suspicious result; and Blocking is less than or equal to 30 percent, and the result is judged to be negative.
2. Coefficient of variation: coefficient of Variation (CV)
The coefficient of variation is calculated as the mean individual variation, expressed as a percentage of the deviation of the mean titer as follows:
coefficient of variation CV = standard deviation (STDEV)/mean blocking rate × 100%
CV is less than or equal to 40%, showing that pigs in the herd have only one balanced and similar reaction.
On the day of inoculating the swine fever vaccine to piglets (blood collection first and then inoculation), namely 30 days old, the antibody blocking rates of all groups of piglets have no statistically significant difference, the variation coefficients are all less than 40%, but the blocking rates are higher, which indicates that the maternal antibodies are higher. Although there is no statistically significant difference between the hog cholera antibody blocking rates of the piglets of each group and the variation coefficients are all less than 40%, the average value of the group is much higher than that of the blank group after the inoculation of the vaccine for 14 days, namely the piglets are 44 days old; although there is no statistically significant difference between the hog cholera antibody blocking rates of the piglets of each group and the variation coefficients are all less than 40%, the average value of the group is much higher than that of the blank group after the inoculation of the piglet at 28 days, namely 58 days old; the group of pigs with higher antibody blocking rate has a value that the blocking rate is lower than 30%, and the blank group has a value that the blocking rate is less than or equal to 30% when 3 pigs have the blocking rate, namely a negative result, so that the invention can delay the reduction of the swine fever antibodies of a plurality of pigs in each group.

Claims (10)

1. A drug combination for preventing and treating piglet infection and improving immunity and swine fever antibody is characterized in that: comprises the following components: ceftiofur hydrochloride, beneficial bacteria, stearate and vegetable oil.
2. The pharmaceutical combination according to claim 1, characterized in that: the weight ratio of each component is as follows: 5-20 parts of ceftiofur hydrochloride, 0.01-0.05 part of beneficial bacteria, 1-10 parts of stearate and 50-80 parts of vegetable oil.
3. The pharmaceutical combination according to claim 1 or 2, wherein the weight ratio of the components is: 5-15 parts of ceftiofur hydrochloride, 0.01-0.03 part of beneficial bacteria, 1-8 parts of stearate and 50-70 parts of vegetable oil.
4. The pharmaceutical combination according to claim 1 or 2, wherein the weight ratio of the components is: 5-10 parts of ceftiofur hydrochloride, 0.01-0.02 part of beneficial bacteria, 1-5 parts of stearate and 50-60 parts of vegetable oil.
5. The pharmaceutical combination according to any one of claims 1 to 4, wherein the beneficial bacterium is Bacillus subtilis or Mycobacterium subtilis.
6. A pharmaceutical combination according to any one of claims 1 to 4, wherein the stearate salt is aluminium stearate or sodium stearate.
7. A pharmaceutical combination according to any one of claims 1 to 4, wherein the vegetable oil is soybean oil or sesame oil.
8. A use method of a drug combination for preventing and treating piglet infection and improving piglet immunity and swine fever antibodies is characterized in that when the piglets are subjected to tooth cutting, tail breaking and castration, the drugs are injected into the head and neck portion once in an intramuscular mode, and each time is 1 ml.
9. The application method of the antibody drug combination for preventing and treating piglet infection, improving piglet immunity and improving piglet plague is characterized in that the drug combination is injected into the head and neck of a weaned piglet once in an intramuscular mode, and the injection amount is 1 ml each time.
10. The application method of the antibody drug combination for preventing and treating piglet infection, improving piglet immunity and improving piglet plague is characterized in that the piglet inoculated with the swine fever vaccine is injected intramuscularly in the neck at the same time, once every time, 1 ml every time.
CN202010101963.6A 2020-02-19 2020-02-19 Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method Pending CN111202753A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010101963.6A CN111202753A (en) 2020-02-19 2020-02-19 Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010101963.6A CN111202753A (en) 2020-02-19 2020-02-19 Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method

Publications (1)

Publication Number Publication Date
CN111202753A true CN111202753A (en) 2020-05-29

Family

ID=70781154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010101963.6A Pending CN111202753A (en) 2020-02-19 2020-02-19 Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method

Country Status (1)

Country Link
CN (1) CN111202753A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107049943A (en) * 2017-05-10 2017-08-18 郑州百瑞动物药业有限公司 Milk cow Ceftiofur Hydrochloride injecta and preparation method thereof
CN107173587A (en) * 2017-07-06 2017-09-19 浙江亚林生物科技股份有限公司 A kind of mixed feed containing selenium-enriched officinal dendrobium stem probiotics and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107049943A (en) * 2017-05-10 2017-08-18 郑州百瑞动物药业有限公司 Milk cow Ceftiofur Hydrochloride injecta and preparation method thereof
CN107173587A (en) * 2017-07-06 2017-09-19 浙江亚林生物科技股份有限公司 A kind of mixed feed containing selenium-enriched officinal dendrobium stem probiotics and preparation method thereof

Similar Documents

Publication Publication Date Title
Maqsood et al. Effect of dietary chitosan on non-specific immune response and growth of Cyprinus carpio challenged with Aeromonas hydrophila
RU2673233C2 (en) Clay product and uses thereof
Palomares et al. Effects of injectable trace minerals on humoral and cell-mediated immune responses to Bovine viral diarrhea virus, Bovine herpes virus 1 and Bovine respiratory syncytial virus following administration of a modified-live virus vaccine in dairy calves
Valpotić et al. Effect of mannan oligosaccharide supplementation on blood and intestinal immune cells, bacteria numbers and performance in weaned pigs
Navarro et al. Oral meloxicam administration in sows at farrowing and Its effects on piglet immunity transfer and growth
US20130156811A1 (en) Method of preventing early lawsonia intracellularis infections
AU2013351213B2 (en) Vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida
JP6484241B2 (en) Swine vaccine against PRRS and Lawsonia intracellularis
JP5865350B2 (en) Vaccine against Mycoplasma hyonyum monnier suitable for administration in the presence of maternally derived antibodies
US20060188550A1 (en) Method of production of animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response
CN111202753A (en) Medicine composition for preventing and treating piglet infection and improving immunity and swine fever antibody and using method
AU2010202344A1 (en) Adjuvanted bovine vaccines
CN104208677A (en) Mixed freeze-dried powder for preventing chicken Newcastle disease, infectious bronchitis, egg drop syndrome, and bird flu, and preparation method thereof
CN108685933A (en) Improve the traditional Chinese medicine ingredients prescription and its preparation method and application of pig immunosuppressive condition
WO2015184101A1 (en) Methods of treating diarrhea in neonatal and young non-human animals
RU2678132C2 (en) Canine health product containing antibodies against canine parvovirus type 2
US7045149B2 (en) Ruminal fluid inoculation of calves
Apic et al. Litters health status and growth parameters in the sows feeding diets supplemented with probiotic Actisaf Sc 47® within pregnancy or lactation
NL2018155B1 (en) Oral vaccine against ruminant respiratory disease
DK2376113T3 (en) PREPARATIONS AND DOSAGE REGIMES WHICH INCLUDES A CLOSTRIDIUM VACCINE AND levamisole
RU2065749C1 (en) Method of prophylaxis of brucellosis in cattle
RU2810134C1 (en) Method of preventing colibacillosis in calves
RU2712237C1 (en) Method for improving the immunobiological reactivity of calves in specific prevention of viral respiratory diseases
RU2020958C1 (en) Method for protection of farm animals from colibacteriosis and salmonellosis
El-shahedy et al. Immunostimulant activity of levamisole to polyvalent FMD vaccine in buffaloes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200529